Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 16/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | TKT | P29401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20796503 | 0.93 | ARF6 (0.67) | ARF6PSDTKT | |
| SCHEMBL20796524 | 0.90 | ARF6 (0.58) | ARF6NPC1KMT2ASMN1; SMN2PSD | |
| SCHEMBL20796643 | 0.90 | ARF6 (0.69) | ARF6PSD | |
| SCHEMBL20796536 | 0.87 | ARF6 (0.72) | ARF6 | |
| SCHEMBL20796645 | 0.87 | ARF6 (0.60) | ARF6PSDTKT | |
| SCHEMBL20796535 | 0.87 | ARF6 (0.71) | ARF6PSD | |
| SCHEMBL22902288 | 0.86 | ARF6 (0.71) | ARF6PSD | |
| SCHEMBL20796543 | 0.86 | ARF6 (0.58) | ARF6NPC1KMT2ASMN1; SMN2PSD | |
| SCHEMBL20796546 | 0.85 | ARF6 (0.59) | ARF6PSDTKT | |
| SCHEMBL20796226 | 0.84 | ARF6 (0.58) | ARF6NPC1KMT2ASMN1; SMN2PSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414442-B2 | ARF6 inhibitors and related methods | NAVIGEN, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. | 2021-01-21 | — | — | US | disclosed |
| WO-2019040499-A2 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | ARF6, ARF1, ARF5 | ARF6 1/4885NPC1 1686/4885KMT2A 4003/4885 |
| US-11414442-B2 | ARF6 inhibitors and related methods | ARF6, ARF1, ARF5 | ARF6 1/4885NPC1 1686/4885KMT2A 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.